GleamWall
中文EN

RLAY Relay Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1812364 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY23.9%
TTM net income YoY1.3%
TTM EPS YoY12.8%
Revenue 3-yr CAGR-26.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,094.6%
Net margin-2,837.0%
FCF margin—
EBITDA margin-3,077.7%

Returns

ROE-41.2%
ROA-37.4%
ROIC (approx.)-41.8%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets9.2%
Debt / equity0.00x
Current ratio14.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$350,000$3.00M$7.00M$0$677,000$7.68M$0
R&D expense$77.14M$76.48M$70.56M$55.41M$68.26M$63.90M$73.81M$68.08M
SG&A expense$13.11M$14.69M$11.03M$12.21M$12.13M$13.63M$18.74M$16.90M
Operating income-$90.25M-$90.82M-$78.59M-$60.63M-$80.39M-$76.85M-$84.87M-$84.98M
Net income-$81.75M-$83.71M-$73.29M-$54.89M-$74.15M-$70.38M-$77.06M-$76.00M
EBITDA-$89.97M-$90.46M-$78.09M-$60.03M-$79.64M-$75.84M-$83.66M-$83.64M
EPS (basic)-0.37-0.41-0.41—-0.43-0.41-0.46—
EPS (diluted)-0.37-0.41-0.41—-0.43-0.41-0.46—
Balance sheet
Cash & equivalents$124.18M$121.19M$204.59M$84.02M$91.56M$113.94M$93.54M$126.41M
Current assets$864.85M$928.08M$658.46M$578.28M$624.01M$680.39M$739.66M$809.20M
PP&E, net$582,000$862,000$1.22M$1.73M$2.36M$3.46M$5.15M$5.91M
Intangibles$4.75M———————
Total assets$901.69M$967.46M$699.61M$621.33M$670.00M$728.84M$799.36M$871.30M
Current liabilities$59.15M$50.80M$29.75M$25.58M$32.60M$32.52M$37.05M$50.73M
Total liabilities$82.70M$77.45M$57.43M$54.27M$62.29M$63.18M$78.28M$93.50M
Shareholders' equity$819.00M$890.01M$642.18M$567.06M$607.71M$665.66M$721.08M$777.79M
Shares outstanding219.50M218.53M189.21M173.87M172.63M171.69M170.48M167.76M
Cash flow statement
Operating cash flow-$63.93M-$54.11M-$51.11M-$44.87M-$62.12M-$55.26M-$73.21M-$57.87M
Capital expenditure$0——$1,000-$1,000$26,000$384,000$0
Free cash flow-$63.93M——-$44.87M-$62.12M-$55.29M-$73.59M-$57.87M
Investing cash flow$62.37M-$353.03M$32.90M$35.46M$39.73M$75.15M$42.47M$29.00M
Financing cash flow$4.42M$323.74M$138.78M$934,000$17,000——$800,000
Depreciation & amortization$280,000$360,000$504,000$599,000$748,000$1.00M$1.21M$1.33M
Stock-based compensation$10.12M$9.18M$10.54M$13.07M$15.53M$14.50M$19.32M$17.64M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.